Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Aservo® EquiHaler® now available in the UK and Ireland
The inhaler marks more than a decade of collaboration between human pharma and animal health businesses.

Product allows medication to be inhaled deep into horses’ lungs.
 
The first inhaled treatment for severe equine asthma is now available in the UK and Ireland.

Manufactured by Boehringer Ingelheim, the Aservo® EquiHaler® marks more than a decade of collaboration between human pharma and Boehringer’s animal health business.

The inhaler incorporates Soft Mist Technology®, which is found in the Respimat® inhaler used in human respiratory disease. This allows the active ingredient to be inhaled deep into the horses’ lungs.

"It's another industry first and is a strong indicator of the commitment that Boehringer Ingelheim has to the health and welfare of horses, and to the investment that we make into continuing to advance therapies through collaboration and innovation,” commented Dr Marc Laemmer, head of equine in UK & Ireland.

“We understand that a product launch in this challenging time for the veterinary profession may seem surprising, but we have had such strong demand from equine vets for the product that we have committed to making Aservo® EquiHaler® available. Our team of territory managers and vet advisers will conduct remote meetings with customers to make sure that they have the information and support they require.”

He continues: “The launch of Aservo® EquiHaler® is a prime example of leveraging innovation efforts of both our human and animal businesses. This has been a strength of ours and I'm excited that we are continuing to further increase the delivery of innovative solutions for horse owners and vets."

The active ingredient in the Aservo® EquiHaler® is ciclesonide - a corticosteroid that is activated directly in the lung, reducing the lower airway inflammation associated with severe equine asthma and reducing the risks commonly associated with systemic corticosteroids.

It does not use a propellant, meaning that using the device does not contribute to harmful greenhouse gas emissions. It has also been manufactured from 50 per cent recycled materials.

Featuring an ergonomic handle, dosing lever, and nostril adapter, the Aservo® EquiHaler®  has been awarded the prestigious Red Dot Award for Product Design.



Become a member or log in to add this story to your CPD history

Hill's Vet Nurse Awards 2020 - get your nominations in!

News Story 1
 Hill's Pet Nutrition are reminding all veterinary nurses and veterinary practices to submit their entries for its 'Pet Slimmer of the Year' competition, 'Managing Weight with Excellence Competition' and the 'Senior Support Nurse of the Year Competition'.

The deadline for the 'Senior Support Nurse of the Year' competition closes on 6 September 2020, while the other competitions will remain open until 14 September 2020. All finalists will have the chance to win up to 500 worth of Love to Shop Vouchers.

To see full terms & conditions or to enter the awards click here

Click here for more...
News Shorts
Webinar highlights increasing threat of Angiostrongylus vasorum and other nematodes

CPD provider elearning.vet has launched a free webinar highlighting the increasing threat of Angiostrongylus vasorum and other nematodes to human and animal health. Hosted by parasitologist Dr Ian Wright, head of ESCAAP UK, the webinar also discusses the most effective treatment and prevention strategies.

Dr Wright said: "With surveys showing deworming frequencies below those recommended by ESCCAP and concerns surrounding over treatment of cats and dogs, there has never been a more important time to examine the importance of routine roundworm prevention. Without adequate control of Toxocara canis and Angiostronglyus vasorum, the impact on owners and their pets can be considerable."